If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMicrosaic Regulatory News (MSYS)

  • There is currently no data for MSYS

Company Update

25 Jun 2024 08:06

RNS Number : 7571T
Microsaic Systems plc
25 June 2024
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

 

FOR IMMEDIATE RELEASE

 

 

Microsaic Systems plc

 

("Microsaic" or the "Company")

Company update

 

Microsaic Systems plc (AIM: MSYS), the developer of microelectronic instruments and provider of integrated Modern Water analytical solutions, is pleased to announce the following update.

 

Research & Development Tax Credit

 

The Company is also pleased to announce it has now received a research and development tax credit from HMRC in the amount of £262,000 for qualifying costs expended in 2022. These costs primarily relate to research and development work by the Company on the pathogen detector for identifying Covid-19 in water. As previously announced, the Company is further developing a device to identify and monitor a wide range of pathogens in water, by adapting the Covid-19 model into an online multi-pathogen detector capable of delivering rapid results.

 

Business Restructuring

 

Having restructured the business at the turn of the year, the Board remains committed to the Company's reset objectives starting this year and to applying a business plan built on the integration of the Microsaic Systems and Modern Water technologies. This technical integration for water testing services is now branded and marketed as 'Tethys Purity' to reflect the broad and comprehensive water testing capabilities that the Company can now offer. Tethys Purity is a modular concept where customers can select the entire suite or a range of devices and services to meet their specific needs, from PFAS detection to toxic water monitoring including pathogen identification. The Company is actively building up partnerships and joint ventures to support its commercial objectives to deliver a total solution for water testing and safety.

 

Bob Moore, Acting Executive Chairman of Microsaic, commented:

 

"We are moving the Company forward by building on our newly combined technologies and enhanced business capabilities. We look forward to completing our worthwhile projects as part of our wider objective of growth and business development, and to building mutually rewarding partnerships to create value for our investors."

 

 

Microsaic Systems plc

Bob Moore, Acting Executive Chairman

+44 (0) 20 3657 0050

via TPI

 

 

Singer Capital Markets (Nominated Adviser)

Aubrey Powell / Oliver Platts

+44 (0)20 7496 3000

 

 

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker / James Pope

+44 (0) 20 3657 0050

 

About Microsaic Systems and Modern Water

Microsaic is highly experienced in microelectronics and development of instrumentation. Having acquired the Modern Water business it has reset, diversified and widened its capabilities into broader based analytical equipment supply and services company with combined technologies resulting in comprehensive water testing capabilities. The Company has an extensive existing and newly acquired innovative patent portfolio in industry-leading technology designed and developed for "Industry 4.0" application serving markets in diversified Industries, Human and Environmental Health. Microsaic's micro-mass spectrometer system and water testing solutions enables analytical detection and characterisation at the point-of-need, whether within a mobile testing capability, conventional laboratory setting, or within a bioprocessing facility for continuous detection of data at multiple steps in the process workflow.

 

Microsaic's products and solutions are commercially available through global markets via a network of regional and local partners, targeting its core laboratory, manufacturing and point-of-need applications.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUVRBRSSUNURR
Date   Source Headline
19th Jun 20177:00 amRNSTrading Statement
15th May 201711:42 amRNSResult of AGM
11th May 20177:00 amRNSMicrosaic Enhances Bioprocessing Capabilities
26th Apr 20177:00 amRNSIntegration with SCPA chromatography software
21st Apr 20177:00 amRNSNotice of AGM
7th Apr 20177:00 amRNSAgreement
21st Mar 20177:00 amRNSFinal Results
13th Mar 20177:00 amRNSChange of registrar
24th Jan 201712:56 pmRNSAppointment of Interim Chairman
13th Dec 20167:00 amRNSTrading Statement
28th Sep 20167:00 amRNSDirectorate Change
21st Sep 20164:39 pmRNSHolding(s) in Company
16th Sep 20161:44 pmRNSDirector/PDMR Shareholding
15th Sep 20161:03 pmRNSHolding(s) in Company
15th Sep 201610:02 amRNSTR-1: Notification of Major Interest in Shares
14th Sep 20165:23 pmRNSHolding(s) in Company
14th Sep 20163:38 pmRNSGrant of Options
13th Sep 20164:46 pmRNSHolding(s) in Company
13th Sep 201610:45 amRNSHolding(s) in Company
13th Sep 20168:40 amRNSHolding(s) in Company
13th Sep 20168:30 amRNSDirector/PDMR Shareholding
12th Sep 201611:53 amRNSResult of GM, Completion of Placing, TVRs
26th Aug 20164:49 pmRNSResult of Placing
26th Aug 20161:15 pmRNSHalf-year Report
26th Aug 20161:15 pmRNSProposed Placing of New Shares
20th Jun 20163:27 pmRNSAGM Statement
13th Jun 20167:00 amRNSChange of Nominated Adviser and Broker
19th May 20167:00 amRNSDistribution of Annual Report and Accounts
13th May 201612:57 pmRNSAGM Change of Date
16th Mar 20167:00 amRNSAnnual Financial Report
8th Mar 20167:00 amRNSDirectorate Change
24th Feb 20167:00 amRNSTrading Statement
14th Jan 20167:00 amRNSAward of Options
21st Dec 20157:00 amRNSDirectorate Change
2nd Dec 20157:04 amRNSTrading Update & Directorate Change
30th Nov 201511:47 amRNSHolding(s) in Company
23rd Oct 201511:41 amRNSHolding(s) in Company
22nd Oct 20151:12 pmRNSHolding(s) in Company
19th Oct 20151:37 pmRNSResults of EGM and Placing
15th Oct 20157:00 amRNSPlacing - Exercise of Additional Demand Option
13th Oct 20153:30 pmRNSDirector/PDMR Shareholding
30th Sep 20157:44 amRNSPlacing of New Shares
30th Sep 20157:00 amRNSInterim Results
20th May 20157:00 amRNSResult of AGM
8th Apr 20158:34 amRNSNotification of Major Interest in Shares
30th Mar 20157:00 amRNSDistribution of Annual Report and Accounts
23rd Mar 20157:00 amRNSAnnual Financial Report
19th Mar 20157:00 amRNSAppoinment of Chief Operating Officer
16th Mar 20157:00 amRNSOEM Supply Agreement with GE Healthcare
6th Jan 20158:40 amRNSExercise of Share Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.